Global Attention Deficit Hyperactivity Disorder (ADHD) Market - Competitive Intelligence Analysis, 2026

Description

The global attention deficit hyperactivity disorder (ADHD) competitive intelligence analysis market is experiencing significant growth as pharmaceutical companies, biotechnology firms, healthcare investors, and research organizations increasingly depend on strategic intelligence to navigate the rapidly evolving ADHD therapeutics landscape. Competitive intelligence analysis provides comprehensive insights into drug pipelines, clinical trial activity, patent landscapes, regulatory developments, licensing agreements, mergers and acquisitions, market positioning, and commercialization strategies. As the number of investigational ADHD therapies continues to expand, organizations are investing heavily in competitive intelligence to strengthen strategic planning, reduce development risks, and identify emerging business opportunities.

The ADHD treatment landscape is evolving beyond traditional stimulant medications toward innovative non-stimulant therapies, extended-release formulations, precision medicine approaches, digital therapeutics, and novel drug delivery technologies. These developments have intensified competition among market participants while increasing the need for continuous monitoring of scientific advances, clinical milestones, intellectual property portfolios, and regulatory decisions. Competitive intelligence enables organizations to benchmark development programs, evaluate unmet clinical needs, assess competitor strategies, and optimize product commercialization.

Digital transformation is further enhancing competitive intelligence capabilities through the adoption of artificial intelligence, machine learning, predictive analytics, natural language processing, and automated data mining platforms. These technologies enable rapid analysis of scientific publications, clinical trial registries, patent filings, regulatory announcements, and commercial activities. Organizations can generate actionable insights more efficiently while improving forecasting accuracy and supporting evidence-based strategic decisions throughout the product lifecycle.

Growing awareness of ADHD among pediatric and adult populations, increasing diagnosis rates, expanding neuroscience research, and rising investment in innovative therapies continue to strengthen market activity. Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations are accelerating therapeutic innovation while creating additional demand for competitive intelligence solutions capable of monitoring evolving market dynamics.

Market Drivers

Expanding ADHD Therapeutic Pipeline

The growing number of investigational ADHD therapies has increased demand for comprehensive competitive intelligence. Organizations continuously evaluate pipeline candidates, mechanisms of action, clinical progress, and commercialization potential to strengthen portfolio management and identify strategic opportunities.

Increasing Strategic Collaborations

Licensing agreements, research collaborations, acquisitions, and co-development partnerships continue to shape the ADHD therapeutics market. Competitive intelligence supports organizations in evaluating partner capabilities, technology platforms, intellectual property assets, and competitive positioning before strategic transactions.

Growing Adoption of Artificial Intelligence

Artificial intelligence is transforming competitive intelligence by enabling automated monitoring of clinical trials, scientific literature, regulatory updates, patent activity, and commercial developments. Advanced analytics improve forecasting accuracy while reducing the time required for strategic assessments.

Rising Investment in Neuroscience Research

Governments, pharmaceutical companies, biotechnology firms, and private investors continue to increase funding for neurodevelopmental disorder research. Expanding research investment strengthens demand for intelligence platforms that support portfolio evaluation, market forecasting, and long-term strategic planning.

Increasing Focus on Adult ADHD

Recognition of ADHD as a lifelong condition has expanded therapeutic development beyond pediatric populations. Growing investment in adult ADHD therapies has created new competitive opportunities that require continuous monitoring of emerging products, clinical evidence, and commercial strategies.

Market Restraints

Rapidly Evolving Competitive Environment

The ADHD therapeutics market changes rapidly through new clinical trial results, regulatory approvals, patent activity, and partnership announcements. Maintaining current intelligence requires continuous monitoring and frequent analytical updates.

Complex Data Integration

Competitive intelligence requires consolidation of scientific publications, clinical trial databases, patent records, regulatory filings, financial disclosures, and commercial information. Integrating these diverse sources into actionable strategic insights remains technically demanding.

High Cost of Advanced Intelligence Solutions

Comprehensive competitive intelligence platforms require investment in specialized databases, artificial intelligence technologies, analytical software, and experienced research professionals. These requirements may limit adoption among smaller biotechnology companies.

Technology and Segment Insights

By Intelligence Type

Pipeline intelligence represents the largest segment of the market. Organizations continuously monitor investigational therapies, development milestones, clinical trial outcomes, regulatory progress, and commercialization timelines to evaluate future competitive positioning.

Clinical trial intelligence continues to expand as companies analyze study design, efficacy endpoints, patient recruitment strategies, safety outcomes, and development timelines to improve future research planning.

Patent intelligence has also become increasingly important as organizations evaluate intellectual property protection, licensing opportunities, and competitive barriers associated with emerging ADHD therapies.

By Therapeutic Focus

Stimulant medications continue to represent an important area of competitive monitoring due to ongoing innovation in extended-release formulations, abuse-deterrent technologies, and improved delivery systems.

Non-stimulant therapies represent one of the fastest-growing intelligence segments as developers pursue differentiated products offering improved safety profiles and reduced misuse potential. Digital therapeutics and combination treatment strategies are also receiving increased competitive attention.

By Technology Platform

Artificial intelligence-powered analytics platforms are increasingly used to automate literature reviews, competitor monitoring, regulatory surveillance, and predictive forecasting.

Machine learning and natural language processing improve extraction of meaningful insights from scientific publications, clinical trial databases, patents, regulatory documents, and healthcare market information.

Cloud-based intelligence platforms continue to gain adoption by providing real-time collaboration, scalable analytics, and continuous market monitoring.

By End User

Pharmaceutical companies remain the largest users of ADHD competitive intelligence due to ongoing investment in drug discovery, clinical development, regulatory strategy, and commercialization planning.

Biotechnology companies increasingly rely on strategic intelligence to evaluate licensing opportunities, attract investment, prioritize pipeline assets, and establish collaborative partnerships.

Healthcare consulting firms, contract research organizations, institutional investors, and academic research organizations also represent important users of competitive intelligence services.

Regional Insights

North America dominates the global ADHD competitive intelligence analysis market due to its advanced pharmaceutical industry, strong biotechnology ecosystem, extensive neuroscience research infrastructure, and high concentration of clinical development programs. The United States remains the leading center for ADHD drug innovation, strategic partnerships, and commercial intelligence activities.

Europe represents a major market supported by established pharmaceutical companies, collaborative academic research networks, and increasing investment in neurodevelopmental disorder research. Germany, the United Kingdom, France, Italy, Spain, and Switzerland continue to play significant roles in ADHD therapeutic development and competitive benchmarking.

Asia Pacific is expected to register the fastest growth during the forecast period. Expanding pharmaceutical innovation, improving regulatory environments, increasing healthcare investment, and growing clinical research capabilities are strengthening demand for competitive intelligence across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually increasing participation in multinational clinical development programs through healthcare modernization, expanding research infrastructure, and greater collaboration with global pharmaceutical companies.

Competitive and Strategic Outlook

The ADHD competitive intelligence analysis market is characterized by specialized healthcare consulting firms, pharmaceutical intelligence providers, biotechnology analytics companies, contract research organizations, and advanced data analytics platforms. Market participants are investing in artificial intelligence, predictive analytics, real-world evidence integration, and automated competitor monitoring to deliver comprehensive strategic intelligence.

Organizations are strengthening capabilities in pipeline benchmarking, clinical trial intelligence, patent analysis, licensing evaluation, regulatory tracking, and commercialization forecasting. Strategic collaborations between pharmaceutical companies, technology providers, academic institutions, and market intelligence organizations continue to improve analytical capabilities and support evidence-based decision-making.

Future competition is expected to focus on real-time competitive monitoring, precision medicine intelligence, digital therapeutics assessment, predictive analytics, and integrated strategic planning platforms capable of supporting increasingly complex ADHD drug development programs.

Conclusion

The global ADHD competitive intelligence analysis market is expected to experience sustained growth as innovation within ADHD therapeutics accelerates and competitive activity continues to expand. Increasing pipeline diversity, rising investment in neuroscience research, growing adoption of artificial intelligence, and expanding strategic collaborations are expected to support long-term market growth. Although challenges related to data integration, rapidly changing competitive environments, and implementation costs remain, advanced competitive intelligence solutions will continue to play a critical role in guiding strategic decision-making across the global ADHD therapeutics industry.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

Product Code: KSI-008893

1. Executive Summary

1.1 Market Overview
1.2 Key Findings
1.3 ADHD Disease Burden and Treatment Outlook
1.4 Commercial Landscape Snapshot
1.5 Competitive Intelligence Highlights
1.6 Pipeline and Innovation Overview
1.7 Regional Market Highlights
1.8 Future Growth Opportunities

2. Disease & Epidemiology Analysis

2.1 Introduction to Attention Deficit Hyperactivity Disorder (ADHD)
- 2.1.1 Definition and Clinical Characteristics
- 2.1.2 Historical Evolution of ADHD Diagnosis
- 2.1.3 Neurobiology and Pathophysiology
- 2.1.4 Genetic and Environmental Risk Factors
2.2 Classification of ADHD
- 2.2.1 Predominantly Inattentive Presentation
- 2.2.2 Predominantly Hyperactive-Impulsive Presentation
- 2.2.3 Combined Presentation
2.3 Disease Burden
- 2.3.1 Global Prevalence and Incidence
- 2.3.2 Pediatric ADHD Epidemiology
- 2.3.3 Adult ADHD Epidemiology
- 2.3.4 Gender-Based Epidemiological Trends
- 2.3.5 Comorbidity Burden
- 2.3.6 Economic and Social Impact
2.4 Diagnosis and Screening
- 2.4.1 DSM-5 Diagnostic Criteria
- 2.4.2 Clinical Assessment Tools
- 2.4.3 Neuropsychological Evaluation
- 2.4.4 Challenges in Early Diagnosis
- 2.4.5 Adult ADHD Underdiagnosis
2.5 Epidemiological Forecast
- 2.5.1 Forecast by Age Group
- 2.5.2 Forecast by ADHD Presentation
- 2.5.3 Forecast by Major Regions

3. Market Dynamics

3.1 Market Overview
3.2 Market Drivers
- 3.2.1 Increasing ADHD Awareness and Diagnosis Rates
- 3.2.2 Rising Adult ADHD Diagnosis
- 3.2.3 Expansion of Novel Non-Stimulant Therapies
- 3.2.4 Growing Mental Health Expenditure
- 3.2.5 Improved Access to Telepsychiatry and Digital Healthcare
3.3 Market Restraints
- 3.3.1 Safety Concerns Associated with Stimulants
- 3.3.2 Drug Abuse and Diversion Risks
- 3.3.3 Generic Competition
- 3.3.4 Treatment Adherence Challenges
- 3.3.5 Regulatory Restrictions on Controlled Substances
3.4 Market Opportunities
- 3.4.1 Expansion of Adult ADHD Therapeutics
- 3.4.2 Long-Acting Drug Formulations
- 3.4.3 Digital Therapeutics and Adjunctive Technologies
- 3.4.4 Precision Medicine Approaches
- 3.4.5 Emerging Markets Expansion
3.5 Market Challenges
- 3.5.1 Drug Shortages and Supply Constraints
- 3.5.2 Limited Biomarkers for Diagnosis
- 3.5.3 Reimbursement Variability
- 3.5.4 Social Stigma Associated with ADHD
3.6 Porter's Five Forces Analysis
- 3.6.1 Bargaining Power of Buyers
- 3.6.2 Bargaining Power of Suppliers
- 3.6.3 Threat of New Entrants
- 3.6.4 Threat of Substitutes
- 3.6.5 Competitive Rivalry
3.7 PESTLE Analysis
- 3.7.1 Political Factors
- 3.7.2 Economic Factors
- 3.7.3 Social Factors
- 3.7.4 Technological Factors
- 3.7.5 Legal Factors
- 3.7.6 Environmental Factors

4. Commercial & Market Access

4.1 Commercial Landscape Overview
4.2 Pricing Analysis
- 4.2.1 Branded versus Generic Products
- 4.2.2 Pricing Trends by Drug Class
- 4.2.3 Regional Pricing Comparison
4.3 Reimbursement Landscape
- 4.3.1 Public Insurance Coverage
- 4.3.2 Private Insurance Coverage
- 4.3.3 Prior Authorization Requirements
- 4.3.4 Controlled Substance Prescribing Policies
4.4 Distribution and Supply Chain Analysis
- 4.4.1 Retail Pharmacies
- 4.4.2 Hospital Pharmacies
- 4.4.3 Specialty Pharmacies
- 4.4.4 Online Pharmacies
- 4.4.5 Supply Chain Challenges
4.5 Market Access Strategies of Leading Companies

5. Innovation & Pipeline Landscape

5.1 Innovation Trends in ADHD Therapeutics
5.2 Novel Mechanisms of Action
- 5.2.1 Selective Norepinephrine Reuptake Inhibitors
- 5.2.2 Dopamine and Norepinephrine Modulators
- 5.2.3 Triple Monoamine Reuptake Inhibitors
- 5.2.4 Orexin Pathway Modulators
- 5.2.5 Other Emerging CNS Targets
5.3 Pipeline Landscape by Development Stage
- 5.3.1 Discovery Stage
- 5.3.2 Preclinical Stage
- 5.3.3 Phase I Pipeline
- 5.3.4 Phase II Pipeline
- 5.3.5 Phase III Pipeline
5.4 Pipeline Landscape by Modality
- 5.4.1 Small Molecules
- 5.4.2 Extended-Release Formulations
- 5.4.3 Digital Therapeutics
- 5.4.4 Combination Therapies
5.5 Clinical Trial Landscape
- 5.5.1 Active Clinical Trials
- 5.5.2 Completed Clinical Trials
- 5.5.3 Trial Distribution by Phase
- 5.5.4 Trial Distribution by Geography
- 5.5.5 Key Trial Endpoints
5.6 Licensing, Collaborations, and Strategic Alliances

6. Treatment Landscape

6.1 Current Treatment Algorithm
6.2 Pharmacological Treatment Landscape
6.3 Stimulant Therapies
- 6.3.1 Methylphenidate-Based Therapies
  - 6.3.1.1 Ritalin (Methylphenidate)
  - 6.3.1.2 Concerta (Methylphenidate Extended Release)
  - 6.3.1.3 Daytrana (Methylphenidate Transdermal System)
  - 6.3.1.4 Jornay PM (Methylphenidate Extended Release)
  - 6.3.1.5 Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
- 6.3.2 Amphetamine-Based Therapies
  - 6.3.2.1 Adderall XR (Mixed Amphetamine Salts)
  - 6.3.2.2 Vyvanse (Lisdexamfetamine Dimesylate)
  - 6.3.2.3 Mydayis (Mixed Amphetamine Salts Extended Release)
  - 6.3.2.4 Adzenys XR-ODT (Amphetamine Extended Release)
  - 6.3.2.5 Dyanavel XR (Amphetamine Extended Release)
6.4 Non-Stimulant Therapies
- 6.4.1 Strattera (Atomoxetine)
- 6.4.2 Qelbree (Viloxazine Extended Release)
- 6.4.3 Intuniv (Guanfacine Extended Release)
- 6.4.4 Kapvay (Clonidine Extended Release)
6.5 Non-Pharmacological Treatment Approaches
- 6.5.1 Behavioral Therapy
- 6.5.2 Cognitive Behavioral Therapy
- 6.5.3 Parent Training Programs
- 6.5.4 Educational Interventions
- 6.5.5 Digital Therapeutics
6.6 Emerging Treatment Paradigms

7. Global Attention Deficit Hyperactivity Disorder (ADHD) Competitive Intelligence Report Size & Forecast

7.1 Global Market Size Analysis
7.2 Historical Market Analysis
7.3 Market Forecast
7.4 Forecast by Therapy Type
7.5 Forecast by Indication
7.6 Forecast by Route of Administration
7.7 Forecast by Distribution Channel
7.8 Forecast by Region
7.9 Scenario Analysis
- 7.9.1 Base Case Scenario
- 7.9.2 Optimistic Scenario
- 7.9.3 Conservative Scenario

8. Global Attention Deficit Hyperactivity Disorder (ADHD) Competitive Intelligence Report Segmentation

8.1 By Therapy Type
- 8.1.1 Stimulants
- 8.1.2 Non-Stimulants
- 8.1.3 Other Emerging Therapeutics
8.2 By Indication
- 8.2.1 Pediatric ADHD
- 8.2.2 Adult ADHD
8.3 By Route of Administration
- 8.3.1 Oral
- 8.3.2 Transdermal
8.4 By End User
- 8.4.1 Hospitals
- 8.4.2 Specialty Clinics
- 8.4.3 Psychiatric Centers
- 8.4.4 Homecare Settings
8.5 By Distribution Channel
- 8.5.1 Hospital Pharmacies
- 8.5.2 Retail Pharmacies
- 8.5.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

9.1 North America
- 9.1.1 Market Size and Growth
- 9.1.2 Demand Drivers
- 9.1.3 Regional Regulatory Overview
- 9.1.4 Competitive Intensity
9.2 Europe
- 9.2.1 Market Size and Growth
- 9.2.2 Demand Drivers
- 9.2.3 Regional Regulatory Overview
- 9.2.4 Competitive Intensity
9.3 Asia-Pacific
- 9.3.1 Market Size and Growth
- 9.3.2 Demand Drivers
- 9.3.3 Regional Regulatory Overview
- 9.3.4 Competitive Intensity
9.4 Latin America
- 9.4.1 Market Size and Growth
- 9.4.2 Demand Drivers
- 9.4.3 Regional Regulatory Overview
- 9.4.4 Competitive Intensity
9.5 Middle East & Africa
- 9.5.1 Market Size and Growth
- 9.5.2 Demand Drivers
- 9.5.3 Regional Regulatory Overview
- 9.5.4 Competitive Intensity

10. Key Countries Analysis

10.1 United States
- 10.1.1 Market Size
- 10.1.2 Epidemiology
- 10.1.3 Regulatory Framework
- 10.1.4 Reimbursement Landscape
- 10.1.5 Key Companies and Products
10.2 Canada
10.3 Germany
10.4 United Kingdom
10.5 France
10.6 Italy
10.7 Spain
10.8 China
10.9 Japan
10.10 India
10.11 South Korea
10.12 Australia
10.13 Brazil
10.14 Mexico
10.15 Saudi Arabia
10.16 South Africa

11. Regulatory & Policy Landscape

11.1 Global Regulatory Overview
11.2 United States
- 11.2.1 FDA Approval Pathways
- 11.2.2 Controlled Substance Regulations
- 11.2.3 Labeling and Safety Requirements
11.3 Europe
- 11.3.1 EMA Approval Framework
- 11.3.2 Pharmacovigilance Requirements
- 11.3.3 Controlled Drug Regulations
11.4 Japan
- 11.4.1 PMDA Approval Framework
- 11.4.2 Post-Marketing Surveillance
11.5 India
- 11.5.1 CDSCO Approval Pathway
- 11.5.2 Narcotic and Psychotropic Regulations
11.6 China
- 11.6.1 NMPA Approval Process
- 11.6.2 Clinical Trial Requirements
- 11.6.3 Post-Marketing Regulations
11.7 Intellectual Property and Patent Landscape
11.8 Regulatory Trends and Future Policy Changes

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Competitive Benchmarking
12.3 Product Portfolio Comparison
12.4 Pipeline Competitiveness Analysis
12.5 Strategic Initiatives
- 12.5.1 Product Launches
- 12.5.2 Label Expansions
- 12.5.3 Partnerships and Collaborations
- 12.5.4 Licensing Agreements
- 12.5.5 Mergers and Acquisitions
12.6 SWOT Analysis of Major Players

13. Company Profiles

13.1 Takeda Pharmaceutical Company Limited
- 13.1.1 Company Overview
- 13.1.2 ADHD Portfolio
  - 13.1.2.1 Vyvanse (Lisdexamfetamine Dimesylate)
  - 13.1.2.2 Adderall XR (Mixed Amphetamine Salts)
- 13.1.3 Key Indications
- 13.1.4 ADHD Pipeline Assets
- 13.1.5 Financial Highlights
- 13.1.6 Strategic Developments
13.2 Eli Lilly and Company
- 13.2.1 Company Overview
- 13.2.2 ADHD Portfolio
  - 13.2.2.1 Strattera (Atomoxetine)
- 13.2.3 Key Indications
- 13.2.4 Pipeline Assets
- 13.2.5 Strategic Developments
13.3 Supernus Pharmaceuticals, Inc.
- 13.3.1 Company Overview
- 13.3.2 ADHD Portfolio
  - 13.3.2.1 Qelbree (Viloxazine Extended Release)
  - 13.3.2.2 Mydayis (Mixed Amphetamine Salts Extended Release)
- 13.3.3 Key Indications
- 13.3.4 Pipeline Assets
- 13.3.5 Strategic Developments
13.4 Johnson & Johnson
- 13.4.1 Company Overview
- 13.4.2 ADHD Portfolio
- 13.4.3 Key Indications
- 13.4.4 Pipeline Assets
- 13.4.5 Strategic Developments
13.5 Novartis AG
- 13.5.1 Company Overview
- 13.5.2 ADHD Portfolio
  - 13.5.2.1 Ritalin (Methylphenidate)
  - 13.5.2.2 Focalin XR (Dexmethylphenidate Extended Release)
- 13.5.3 Key Indications
- 13.5.4 Pipeline Assets
- 13.5.5 Strategic Developments
13.6 Collegium Pharmaceutical, Inc
- 13.6.1 Company Overview
- 13.6.2 ADHD Portfolio
  - 13.6.2.1 Jornay PM (Methylphenidate Extended Release)
- 13.6.3 Key Indications
- 13.6.4 Pipeline Assets
- 13.6.5 Strategic Developments
13.7 Teva Pharmaceuticals
- 13.7.1 Company Overview
- 13.7.2 ADHD Portfolio
  - 13.7.2.1 Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
- 13.7.3 Key Indications
- 13.7.4 Pipeline Assets
- 13.7.5 Strategic Developments
13.8 Tris Pharma, Inc.
- 13.8.1 Company Overview
- 13.8.2 ADHD Portfolio
  - 13.8.2.1 Dyanavel XR (Amphetamine Extended Release)
- 13.8.3 Key Indications
- 13.8.4 Pipeline Assets
- 13.8.5 Strategic Developments
13.9 Neos Therapeutics, Inc.
- 13.9.1 Company Overview
- 13.9.2 ADHD Portfolio
  - 13.9.2.1 Adzenys XR-ODT (Amphetamine Extended Release)
- 13.9.3 Key Indications
- 13.9.4 Pipeline Assets
- 13.9.5 Strategic Developments
13.10 Aurobindo Pharma
- 13.10.1 Company Overview
- 13.10.2 ADHD Portfolio
- 13.10.3 Key Indications
- 13.10.4 Verified Pipeline Assets
- 13.10.5 Strategic Developments

14. Future Outlook

14.1 Future Market Outlook to Forecast Period
14.2 Emerging Technologies in ADHD Management
14.3 Evolution of Adult ADHD Treatment
14.4 Novel Drug Targets and Next-Generation Therapies
14.5 Digital Therapeutics and AI-Based Care Models
14.6 Competitive Scenario Evolution
14.7 Strategic Recommendations for Stakeholders

15. Methodology

15.1 Research Objectives
15.2 Scope of the Study
15.3 Market Definition
15.4 Data Collection Methodology
15.5 Secondary Research Sources
15.6 Primary Research Framework
15.7 Epidemiology Modeling Approach
15.8 Market Forecasting Methodology
15.9 Competitive Intelligence Framework
15.10 Data Validation and Triangulation
15.11 Assumptions and Limitations
15.12 Abbreviations and Definitions